DCOY Decoy Therapeutics Inc.

NEUTRAL Impact: 3/10 DEFA14A
Horizon weeks Filed Jun 4, 2026 Processed 1d 7h ago SEC 0001193125-26-256546
Proxy solicitation materials

Price Chart

Loading chart...

Executive Summary

Decoy Therapeutics Inc. filed a DEFA14A (definitive additional proxy soliciting materials) providing notice of its 2026 Annual Meeting to be held virtually on July 14, 2026. The board recommends voting FOR all three proposals: election of three director nominees (Patricia Gauthier, Jonathan Lieber, Frederick E. Pierce), non-binding advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor for FY 2026. This is a routine management proxy solicitation with no dissident or activist campaign disclosed.

Actionable Insight

Routine annual meeting proxy notice with no contested items or activist involvement. Monitor for any dissident filings (DFAN14A) ahead of the July 14 meeting date. The $4M market cap and bearish analyst consensus suggest limited institutional interest — vote outcome is unlikely to move the stock.

Key Facts

  • Annual Meeting scheduled for July 14, 2026, held virtually
  • Three director nominees: Patricia Gauthier, Jonathan Lieber, Frederick E. Pierce
  • Board recommends FOR all three proposals: director election, say-on-pay, auditor ratification
  • Ernst & Young LLP proposed as independent registered public accounting firm for FY ending Dec 31, 2026
  • Record date and share counts not disclosed in this filing
  • Market cap of $4M with 0% analyst bullish consensus (0 Strong Buy, 0 Buy, 3 Hold, 1 Sell, 2 Strong Sell)

Financial Impact

No financial figures disclosed in this filing

Risk Factors

  • No dissident or activist campaign identified — low risk of contested vote
  • Micro-cap with $4M market cap and negative analyst sentiment (0% bullish) may face low shareholder turnout

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-256546
Document: 0001193125-26-256546-index-headers.html0001193125-26-256546
Document: 0001193125-26-256546-index.html0001193125-26-256546
Document: 0001193125-26-256546.txt0001193125-26-256546
4 reports for DCOY
Performance horizon
Filters
Rows
Reports for DCOY — sortable, filterable
Type Now
Jun 4, 2026
1d ago
DEFA14A
NEUTRAL ★ 3/10
$8.19 awaiting T+20awaiting T+20$6.61 (−19.28%)
Apr 30, 2026
5w ago
10-K/A
NEUTRAL ★ 2/10
$6.05 $7.91▲ +30.74%▲ +25.78%$6.61 (+9.27%)
Apr 2, 2026
9w ago
8-K
MIXED ★ 6/10
$5.80 $6.05▲ +4.31%▼ −5.57%$6.61 (+13.98%)
Mar 5, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$7.00 $5.80▼ −17.10%▼ −13.31%$6.61 (−5.51%)
Showing 4 of 4

US Market Status

Market Open — Closes in 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access